RETROVIR

LOE Approaching

zidovudine

NDAINJECTIONINJECTABLEPriority Review
Approved
Feb 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Nucleoside Reverse Transcriptase Inhibitors

Pharmacologic Class:

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Clinical Trials (5)

NCT00002096Phase 1Completed

A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine

24 enrolled
Cytomegalovirus InfectionsHIV Infections
NCT00377065N/AApproved For Marketing

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

HIV Infections
NCT00000657Phase 2Completed

Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex

80 enrolled
AIDS Dementia ComplexHIV Infections
NCT00000678Phase 2Completed

Dideoxycytidine ( Ro 24-2027 ) A Randomized, Open-Label, Comparative Study of Dideoxycytidine ( ddC ) Versus Zidovudine ( AZT ) in Patients With AIDS or Advanced ARC Who Have Received Long-Term AZT Therapy.

320 enrolled
HIV Infections
NCT00002190Phase 2Completed

A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

30 enrolled
HIV Infections